BioLight Life Sciences Ltd. (TLV: BOLT)
Israel
· Delayed Price · Currency is ILS · Price in ILA476.10
-8.90 (-1.84%)
Dec 22, 2024, 3:49 PM IDT
BioLight Life Sciences Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 0.2 | 0.12 | 0.06 | 0 | 0.03 | - | Upgrade
|
| Revenue Growth (YoY) | 117.58% | 87.30% | 2000.00% | -90.32% | - | - | Upgrade
|
| Gross Profit | 0.2 | 0.12 | 0.06 | 0 | 0.03 | - | Upgrade
|
| Selling, General & Admin | 6.59 | 6.25 | 6.86 | 6.27 | 6.66 | 6.34 | Upgrade
|
| Research & Development | 3.56 | 4.52 | 3.53 | 4.34 | 3.99 | 5.06 | Upgrade
|
| Other Operating Expenses | - | - | - | - | 0.77 | -0.88 | Upgrade
|
| Operating Expenses | 10.15 | 10.77 | 10.39 | 10.61 | 11.42 | 10.52 | Upgrade
|
| Operating Income | -9.95 | -10.65 | -10.32 | -10.6 | -11.39 | -10.52 | Upgrade
|
| Interest Expense | -0 | -0.08 | -0.07 | -0.02 | -0.04 | -0.03 | Upgrade
|
| Interest & Investment Income | 0.28 | 0.26 | 0.01 | 0.07 | 0.3 | 0.67 | Upgrade
|
| Earnings From Equity Investments | -0.34 | -0.39 | -0.63 | -0.28 | -0.38 | -1.42 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.04 | 0.04 | 0.57 | -0.88 | -1.19 | -3.43 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.96 | -0.96 | 0.3 | -0.27 | 0.03 | 0.18 | Upgrade
|
| EBT Excluding Unusual Items | -10.93 | -11.77 | -10.14 | -11.98 | -12.67 | -14.56 | Upgrade
|
| Gain (Loss) on Sale of Investments | 3.62 | -15.72 | 1.45 | 10.07 | -1.43 | 0.17 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 0.07 | - | Upgrade
|
| Pretax Income | -7.31 | -27.49 | -8.69 | -1.91 | -14.04 | -14.39 | Upgrade
|
| Income Tax Expense | - | - | - | -1.57 | 0.14 | -0.75 | Upgrade
|
| Earnings From Continuing Operations | -7.31 | -27.49 | -8.69 | -0.34 | -14.17 | -13.64 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | -0.92 | -0.94 | Upgrade
|
| Net Income to Company | -7.31 | -27.49 | -8.69 | -0.34 | -15.09 | -14.58 | Upgrade
|
| Minority Interest in Earnings | 1.15 | 1.47 | 0.84 | 0.72 | 1.7 | 1.99 | Upgrade
|
| Net Income | -6.16 | -26.02 | -7.85 | 0.38 | -13.38 | -12.59 | Upgrade
|
| Net Income to Common | -6.16 | -26.02 | -7.85 | 0.38 | -13.38 | -12.59 | Upgrade
|
| Shares Outstanding (Basic) | 5 | 5 | 5 | 5 | 5 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 5 | 5 | 5 | 5 | 5 | 5 | Upgrade
|
| Shares Change (YoY) | 1.16% | 1.70% | -0.41% | 0.94% | - | 7.35% | Upgrade
|
| EPS (Basic) | -1.32 | -5.60 | -1.72 | 0.08 | -2.95 | -2.77 | Upgrade
|
| EPS (Diluted) | -1.32 | -5.60 | -1.72 | 0.08 | -2.95 | -2.77 | Upgrade
|
| Free Cash Flow | -8.87 | -10.99 | -9.57 | -10.63 | -13.49 | -15.39 | Upgrade
|
| Free Cash Flow Per Share | -1.91 | -2.37 | -2.10 | -2.32 | -2.97 | -3.39 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - | Upgrade
|
| Operating Margin | -5026.26% | -9026.27% | -16384.13% | -353433.33% | -36751.61% | - | Upgrade
|
| Profit Margin | -3109.60% | -22050.85% | -12455.56% | 12733.33% | -43167.74% | - | Upgrade
|
| Free Cash Flow Margin | -4480.81% | -9315.25% | -15193.65% | -354333.33% | -43529.03% | - | Upgrade
|
| EBITDA | -9.91 | -10.6 | -10.25 | -10.07 | -10.84 | -9.98 | Upgrade
|
| D&A For EBITDA | 0.04 | 0.05 | 0.08 | 0.53 | 0.56 | 0.54 | Upgrade
|
| EBIT | -9.95 | -10.65 | -10.32 | -10.6 | -11.39 | -10.52 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.